Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Transcept Pharma Receives $10 Mln Milestone Payment From Purdue - Quick Facts

RELATED NEWS
Trade TSPT now with 

Transcept Pharmaceuticals Inc. (TSPT: Quote) said Wednesday it received a $10 million milestone payment from Purdue Pharma LP in connection with the listing of Intermezzo formulation patents in the FDA Orange Book on December 15, 2011.

The milestone payment was made under the terms of the agreement between Purdue and Transcept for the commercialization of insomnia drug Intermezzo in the US. Purdue plans to launch Intermezzo in the second quarter of 2012 and to invest about $100 million to support marketing during the first year of commercialization.

On November 23, 2011, the FDA approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.

Transcept reported cash, cash equivalents and marketable securities of $54.1 million at September 30, 2011, and excludes the $10 million payment received today.

Click here to receive FREE breaking news email alerts for Transcept Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
President Barack Obama is scheduled to travel to the headquarters of the Centers for Disease Control and Prevention in Atlanta, Georgia, on Tuesday to outline steps the U.S. will take to help combat the Ebola outbreak in West Africa. After recovering from an initial move to the downside, stocks have moved mostly higher over the course of the trading day on Tuesday. The major average have all turned positive, with the Nasdaq and the S&P 500 bouncing off their worst levels in almost a month. Senate Republicans once again voted Monday to block a Democratic bill aimed at narrowing the national gender wage gap. The Senate voted 52 to 40 in favor of limiting debate on the Paycheck Fairness Act, falling well short of the 60 votes required.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.